CU23413B7 - Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos - Google Patents

Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos

Info

Publication number
CU23413B7
CU23413B7 CU20050031A CU20050031A CU23413B7 CU 23413 B7 CU23413 B7 CU 23413B7 CU 20050031 A CU20050031 A CU 20050031A CU 20050031 A CU20050031 A CU 20050031A CU 23413 B7 CU23413 B7 CU 23413B7
Authority
CU
Cuba
Prior art keywords
formula
new
compounds
derivatives useful
antiproliferative agents
Prior art date
Application number
CU20050031A
Other languages
English (en)
Inventor
Huifen Faye Wang
Joseph Peter Lyssikatos
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CU23413B7 publication Critical patent/CU23413B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

La invención se refiere a compuestos de fórmula 1 ESPACIO PARA FÓRMULA y a sales, profármacos, y solvatos farmacéuticamente aceptables de los mismos, donde R1, R2, R3 y R4 son como se han definido anteriormente. La invención también se refiere a procedimientos para tratar el crecimiento celular anormal, tal como cáncer, en mamíferos administrando los compuestos de fórmula 1 y a composiciones farmacéuticas para tratar tales trastornos que contienen los compuestos de fórmula 1. La invención también se refiere a procedimientos para preparar los compuestos de fórmula 1.
CU20050031A 2002-08-28 2005-02-14 Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos CU23413B7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40652402P 2002-08-28 2002-08-28
US41704702P 2002-10-08 2002-10-08

Publications (1)

Publication Number Publication Date
CU23413B7 true CU23413B7 (es) 2009-09-08

Family

ID=31981411

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050031A CU23413B7 (es) 2002-08-28 2005-02-14 Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos

Country Status (41)

Country Link
US (1) US7071337B2 (es)
EP (1) EP1594858B1 (es)
JP (1) JP4551771B2 (es)
KR (2) KR20070086768A (es)
CN (1) CN1319966C (es)
AP (1) AP2005003237A0 (es)
AR (1) AR041055A1 (es)
AT (1) ATE445610T1 (es)
AU (1) AU2003250499B2 (es)
BR (1) BRPI0313942C1 (es)
CA (1) CA2495577C (es)
CR (1) CR7698A (es)
CU (1) CU23413B7 (es)
CY (1) CY1110580T1 (es)
DE (1) DE60329715D1 (es)
DK (1) DK1594858T3 (es)
DO (1) DOP2003000694A (es)
EA (1) EA008448B1 (es)
EC (1) ECSP055633A (es)
ES (1) ES2333219T3 (es)
GE (1) GEP20064005B (es)
HK (1) HK1078571A1 (es)
HN (1) HN2003000257A (es)
HR (1) HRP20050191B1 (es)
IL (1) IL166832A (es)
IS (1) IS2738B (es)
MA (1) MA27389A1 (es)
MX (1) MXPA05001256A (es)
MY (1) MY139357A (es)
NO (1) NO20051303L (es)
NZ (1) NZ538427A (es)
OA (1) OA12916A (es)
PA (1) PA8580301A1 (es)
PE (1) PE20050131A1 (es)
PL (1) PL377678A1 (es)
PT (1) PT1594858E (es)
RS (1) RS20050180A (es)
SI (1) SI1594858T1 (es)
TW (1) TW200407131A (es)
UY (1) UY27952A1 (es)
WO (1) WO2004020431A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1641780T3 (da) * 2003-06-24 2009-02-02 Pfizer Prod Inc Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
CA2582479C (en) * 2004-10-07 2011-07-12 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
BRPI0608096A2 (pt) 2005-04-26 2009-11-10 Pfizer anticorpos p-caderina
UA94060C2 (ru) 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
BRPI0809998B8 (pt) 2007-04-03 2021-05-25 Array Biopharma Inc composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
MX2010012718A (es) * 2008-05-21 2011-04-04 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4] triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
CA2809892C (en) 2010-09-02 2019-05-28 Merck Patent Gmbh Pyrazolopyridinone derivatives as lpa receptor antagonists
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
US11642340B2 (en) 2012-09-26 2023-05-09 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
RS58328B1 (sr) * 2014-10-31 2019-03-29 Genoscience Pharma Sas Supstituisani 2,4 diamino-hinolini kao novi antitumorski agensi
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
DK3452465T3 (da) 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
WO2018085292A1 (en) 2016-11-02 2018-05-11 Arog Pharmaceuticals, Inc. Crenolanib for treating flt3 mutated proliferative disorders associated mutations
CN107382984B (zh) * 2017-08-24 2020-07-10 扬州市三药制药有限公司 一种治疗白血病药物的制备方法
CN107382983B (zh) * 2017-08-24 2020-08-07 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
CN110840893A (zh) 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN117447376A (zh) * 2019-12-09 2024-01-26 苏州恩华生物医药科技有限公司 连双环结构sigma-1受体抑制剂
WO2022019998A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
IL300205A (en) * 2020-08-05 2023-03-01 Massachusetts Gen Hospital Salt-inducible kinase inhibitors
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN113683594B (zh) * 2021-09-07 2022-12-27 曲靖师范学院 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用
JP2023063189A (ja) 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CA2393026A1 (en) * 1999-11-30 2001-06-07 Paul A. Wender Bryostatin analogues, synthetic methods and uses
JP2008002005A (ja) * 2006-06-21 2008-01-10 Shimada Shoji Kk 衣服用パッド

Also Published As

Publication number Publication date
UY27952A1 (es) 2004-03-31
CA2495577A1 (en) 2004-03-11
HK1078571A1 (en) 2006-03-17
EA008448B1 (ru) 2007-06-29
MA27389A1 (fr) 2005-06-01
MXPA05001256A (es) 2005-06-08
PE20050131A1 (es) 2005-03-21
CN1678604A (zh) 2005-10-05
WO2004020431A3 (en) 2004-05-13
EP1594858A2 (en) 2005-11-16
BRPI0313942B8 (pt) 2020-08-04
US7071337B2 (en) 2006-07-04
PA8580301A1 (es) 2005-05-24
BR0313942A (pt) 2005-07-12
CA2495577C (en) 2010-06-15
NZ538427A (en) 2007-04-27
TW200407131A (en) 2004-05-16
EP1594858B1 (en) 2009-10-14
NO20051303L (no) 2005-05-18
IL166832A (en) 2011-03-31
AU2003250499A1 (en) 2004-03-19
AP2005003237A0 (en) 2005-03-31
ECSP055633A (es) 2005-04-18
SI1594858T1 (sl) 2010-01-29
BRPI0313942B1 (pt) 2019-06-04
IS2738B (is) 2011-06-15
DE60329715D1 (de) 2009-11-26
AR041055A1 (es) 2005-04-27
JP4551771B2 (ja) 2010-09-29
KR100816166B1 (ko) 2008-03-21
CR7698A (es) 2007-11-23
DOP2003000694A (es) 2004-02-29
KR20050036984A (ko) 2005-04-20
PL377678A1 (pl) 2006-02-06
KR20070086768A (ko) 2007-08-27
AU2003250499B2 (en) 2009-04-23
ES2333219T3 (es) 2010-02-18
CY1110580T1 (el) 2015-04-29
JP2006501309A (ja) 2006-01-12
HN2003000257A (es) 2004-12-01
MY139357A (en) 2009-09-30
OA12916A (en) 2006-10-13
DK1594858T3 (da) 2009-12-14
IS7660A (is) 2005-01-20
HRP20050191A2 (en) 2005-10-31
ATE445610T1 (de) 2009-10-15
BRPI0313942C1 (pt) 2021-05-25
US20050124599A1 (en) 2005-06-09
WO2004020431A2 (en) 2004-03-11
EA200500174A1 (ru) 2005-08-25
RS20050180A (en) 2007-08-03
CN1319966C (zh) 2007-06-06
GEP20064005B (en) 2006-12-25
HRP20050191A9 (hr) 2013-11-22
HRP20050191B1 (hr) 2013-12-20
PT1594858E (pt) 2009-12-14

Similar Documents

Publication Publication Date Title
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
SV1999000252A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer ref.pc10113abcz
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
AR028985A1 (es) Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
PA8480201A1 (es) Derivados de quinilin-2-ona utiles como agentes contra el cancer
CR20110380A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
DOP2002000519A (es) Procedimiento para la preparación de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal
ECSP003793A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ECSP993260A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer
UY26785A1 (es) Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal
UY26460A1 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos.
ECSP993117A (es) Derivados de quinolin -2 - ona utiles como agentes contra el cancer
ECSP993118A (es) Derivados de quinolin -2 -ona alquinilsustituidos utiles como agentes anticancerosos
UY27557A1 (es) Procedimiento para la preparación de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
DOP2003000786A (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal.
UY28131A1 (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal
ECSP992984A (es) Derivados de isotiazol utiles como agentes anticancerosos
DOP2003000595A (es) Indolil-urea derivado de tienopiridinas utiles como agentes antiangionicos,y procedimientos para su uso

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)